Breaking News

Pharm-Olam Selected as CRO for Phase 2 Lymphoma Study

Infinity Pharma previously partnered with the CRO for another Phase II study

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pharm-Olam International, a multi-national, full-service clinical research organization (CRO) to the biopharmaceutical and medical device industries, has been selected as the CRO for Infinity Pharmaceuticals for the conduct of Infinity’s Fresco study, a Phase II clinical trial of an investigational medicine for the treatment of relapsed/refractory follicular lymphoma. “We are extremely pleased to continue our collaboration with Infinity,” said Sanjiv Suri, chief executive officer, Pharm-Olam....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters